The Coming Psychedelic Boom
Warning to all investors: There's a coming boom that might make the CBD craze look like an outdated investment.

NYSE:BIO - Bio-Rad Laboratories Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $700.00
  • Forecasted Upside: 12.03 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.85 (-0.14%)

This chart shows the closing price for BIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bio-Rad Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIO

Analyst Price Target is $700.00
▲ +12.03% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Bio-Rad Laboratories in the last 3 months. The average price target is $700.00, with a high forecast of $750.00 and a low forecast of $650.00. The average price target represents a 12.03% upside from the last price of $624.82.

This chart shows the closing price for BIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
The Coming Psychedelic Boom
Warning to all investors: There's a coming boom that might make the CBD craze look like an outdated investment.

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Bio-Rad Laboratories. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2021CitigroupBoost Price TargetBuy$675.00 ➝ $750.00Low
2/5/2021Jefferies Financial GroupBoost Price TargetBuy$660.00 ➝ $725.00Low
10/30/2020Smith Barney CitigroupBoost Price Target$625.00 ➝ $675.00Medium
10/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$590.00 ➝ $650.00High
9/3/2020Jefferies Financial GroupReiterated RatingBuy ➝ Market Perform$666.00Medium
9/3/2020Wells Fargo & CompanyReiterated RatingBuy$590.00Medium
7/31/2020Wells Fargo & CompanyBoost Price TargetOverweight$525.00 ➝ $590.00High
7/31/2020CitigroupBoost Price TargetBuy$525.00 ➝ $625.00High
7/30/2020Wells Fargo & CompanyReiterated RatingBuyHigh
5/21/2020Wells Fargo & CompanyBoost Price TargetOverweight$495.00 ➝ $525.00Low
5/7/2020CitigroupBoost Price TargetBuy$480.00 ➝ $525.00Low
4/20/2020CitigroupBoost Price TargetBuy$425.00 ➝ $480.00Low
3/30/2020Wells Fargo & CompanyLower Price TargetOverweight$440.00 ➝ $385.00High
3/26/2020BarclaysLower Price TargetOverweight$435.00 ➝ $430.00Medium
3/20/2020CitigroupLower Price TargetBuy$450.00 ➝ $425.00High
3/3/2020CitigroupReiterated RatingBuy$450.00N/A
2/14/2020Wells Fargo & CompanyBoost Price TargetOverweight$430.00 ➝ $440.00High
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$430.00Low
1/6/2020CitigroupInitiated CoverageBuy$450.00High
8/20/2019The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$400.00High
8/2/2019BarclaysBoost Price TargetOverweight$350.00 ➝ $380.00High
5/9/2019Deutsche Bank AktiengesellschaftBoost Price TargetBuy$350.00 ➝ $375.00High
5/9/2019BarclaysBoost Price TargetOverweight$340.00 ➝ $350.00High
3/1/2019Deutsche Bank AktiengesellschaftBoost Price TargetBuy ➝ Buy$330.00 ➝ $350.00Medium
3/1/2019BarclaysBoost Price TargetOverweight ➝ Overweight$315.00 ➝ $340.00Medium
1/3/2019BarclaysUpgradeEqual Weight ➝ Overweight$315.00Medium
11/2/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$345.00 ➝ $315.00N/A
10/17/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$350.00Low
9/24/2018Jefferies Financial GroupReiterated RatingBuy$420.00High
9/20/2018Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$335.00Low
9/5/2018BarclaysInitiated CoverageEqual Weight$345.00High
8/8/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$325.00 ➝ $355.00High
3/20/2018Wells Fargo & CompanyBoost Price TargetOutperform$280.00 ➝ $290.00Low
2/28/2018Wells Fargo & CompanyLower Price TargetOutperform ➝ Outperform$290.00 ➝ $280.00Medium
2/28/2018Jefferies Financial GroupBoost Price TargetTop Pick ➝ Buy$325.00High
2/28/2018CitigroupBoost Price TargetBuy$325.00High
2/16/2018CL KingDowngradeBuy ➝ NeutralMedium
11/29/2017Wells Fargo & CompanyReiterated RatingOutperform$250.00 ➝ $290.00High
9/18/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$255.00Low
7/14/2017Jefferies Financial GroupReiterated RatingBuy$275.00Low
7/13/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$250.00High
6/28/2017Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$220.00 ➝ $195.00High
4/27/2017Jefferies Financial GroupReiterated RatingBuy$250.00Low
4/11/2017Jefferies Financial GroupReiterated RatingBuy$250.00Low
3/14/2017Jefferies Financial GroupBoost Price TargetBuy$250.00 ➝ $300.00High
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$195.00N/A
12/4/2016Jefferies Financial GroupReiterated RatingBuy$225.00N/A
10/12/2016CL KingInitiated CoverageBuy$180.00N/A
9/7/2016Jefferies Financial GroupBoost Price TargetBuy$200.00 ➝ $225.00N/A
(Data available from 6/23/2016 forward)
Bio-Rad Laboratories logo
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Read More

Today's Range

Now: $624.82
Low: $621.08
High: $626.90

50 Day Range

MA: $608.02
Low: $579.58
High: $649.04

52 Week Range

Now: $624.82
Low: $425.43
High: $689.00


59,891 shs

Average Volume

181,506 shs

Market Capitalization

$18.60 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Bio-Rad Laboratories?

The following equities research analysts have issued reports on Bio-Rad Laboratories in the last year: Citigroup Inc., Jefferies Financial Group Inc., Smith Barney Citigroup, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for BIO.

What is the current price target for Bio-Rad Laboratories?

4 Wall Street analysts have set twelve-month price targets for Bio-Rad Laboratories in the last year. Their average twelve-month price target is $700.00, suggesting a possible upside of 12.0%. Citigroup Inc. has the highest price target set, predicting BIO will reach $750.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $650.00 for Bio-Rad Laboratories in the next year.
View the latest price targets for BIO.

What is the current consensus analyst rating for Bio-Rad Laboratories?

Bio-Rad Laboratories currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BIO will outperform the market and that investors should add to their positions of Bio-Rad Laboratories.
View the latest ratings for BIO.

What other companies compete with Bio-Rad Laboratories?

How do I contact Bio-Rad Laboratories' investor relations team?

Bio-Rad Laboratories' physical mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company's listed phone number is 510-724-7000 and its investor relations email address is [email protected] The official website for Bio-Rad Laboratories is

The Coming Psychedelic Boom
Warning to all investors: There's a coming boom that might make the CBD craze look like an outdated investment.